Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 4'-n-benzoyl Staurosporine
2. 4'-n-benzoylstaurosporine
3. Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1h,8h-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-n-methyl-, (8alpha,9beta,10beta,12alpha)-
4. Benzoylstaurosporine
5. Cgp 41 251
6. Cgp 41251
7. Cgp-41251
8. N-((9s,10r,11r,13r)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methylbenzamide
9. Pkc 412
10. Pkc-412
11. Pkc412
12. Rydapt
1. 120685-11-2
2. Pkc-412
3. Pkc412
4. Cgp 41251
5. 4'-n-benzoylstaurosporine
6. Pkc 412
7. Rydapt
8. Cgp-41251
9. Benzoylstaurosporine
10. N-benzoylstaurosporine
11. Id912s5von
12. Nvp-pkc412
13. Chembl608533
14. Chebi:63452
15. Nsc-656576
16. N-((9s,10r,11r,13r)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methylbenzamide
17. N-[(5s,6r,7r,9r)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-n-methylbenzamide
18. Midostaurin [inn]
19. Cgp 41 251
20. Midostaurin [usan:inn]
21. Unii-id912s5von
22. Cgp41251
23. Cgp 41231
24. Rydapt (tn)
25. Midostaurin(pkc412)
26. 4-n-benzoylstaurosporine
27. Midostaurin [mi]
28. Staurosporine, N-benzoyl
29. Midostaurin [jan]
30. Midostaurin [usan]
31. Midostaurin [mart.]
32. Midostaurin [who-dd]
33. Midostaurin (jan/usan/inn)
34. Gtpl5702
35. Schembl8295379
36. Midostaurin [orange Book]
37. Hms3229k17
38. Ex-a1741
39. Bdbm50326053
40. Cgp-41521
41. Mfcd00871372
42. Nsc800791
43. S8064
44. Akos024457372
45. Zinc100013130
46. Ccg-101288
47. Cs-3331
48. Db06595
49. Nsc 656576
50. Nsc-800791
51. Ncgc00241102-01
52. Ncgc00241102-02
53. Ncgc00241102-05
54. Ncgc00484987-03
55. Ac-31929
56. Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1h,8h-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-n-methyl-, (8alpha,9beta,10beta,12alpha)-
57. Hy-10230
58. C71714
59. D05029
60. J-004379
61. Q6842945
62. Brd-k13646352-001-01-2
63. [9s-(9?,10?,11?,13?)]-n-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1h,9h-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-n-methylbenzamide
64. Benzamide, N-((9s,10r,11r,13r)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methyl-
65. N-[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-4-yl]-n-methylbenzamide
66. N-[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-n-methyl-benzamide
67. N-[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-n-methylbenzamide
Molecular Weight | 570.6 g/mol |
---|---|
Molecular Formula | C35H30N4O4 |
XLogP3 | 4.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 570.22670545 g/mol |
Monoisotopic Mass | 570.22670545 g/mol |
Topological Polar Surface Area | 77.7 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 1140 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 1 | |
---|---|
Drug Name | RYDAPT |
Active Ingredient | MIDOSTAURIN |
Company | NOVARTIS PHARMS CORP (Application Number: N207997. Patents: 7973031, 8222244, 8575146) |
Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
FDA Label
Rydapt is indicated:
- in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4. 2);
- as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).
It targets multiple WT and mutated kinases that, when activated, constitutively stimulate aberrant signalling cascades that lead to malignancies such as AML and ASM. Alternative pharmacodynamic effect of midostaurin in prolonging QTc intervals was not clinically significant in patients with advanced SM or AML when compared to placebo. Midostaurin is therapeutically beneficial as a combination therapy for patients undergoing chemotherapy.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX - Other protein kinase inhibitors
L01EX10 - Midostaurin
Absorption
The time to reach maximum concentration ranges from 1-3 hrs in fasting patients. The maximum concentration and the time it takes to reach this concentration is reduced up to 20% in presence of a standard meal.
Route of Elimination
Accounting for 95% of recovered dose eliminated through fecal excretion, 91% was determined as metabolites and 4% as unchanged parent drug. Remaining 5% of the recovered dose is eliminated via renal excretion.
Volume of Distribution
The Vd of midostaurin is 95.2L. The parent drug and its main metabolites (CGP62221, CGP52421) are distributed in plasma in vitro.
Clearance
The clearance values of during the initial formation of metabolites are 1.47 L/h for CGP62221 metabolite and 0.501 L/h for CGP52421. 28 days following the oral administration of midostaurin, the clearance of CGP52421 may increase up to 5.2 fold in a recommended dose of 25 mg, resulting in a 2.1- to 2.5-fold increase in total clearance of midostaurin.
Midostaurin is primarily metabolized into CGP62221 and CGP52421 via hepatic CYP3A4 enzymatic activity. The metabolism of CGP62221 takes place initially in a linear relationship whereas CGP52421 formation is an inducible process.
Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs for CGP52421.
It potently inhibits multiple receptor tyrosine kinases. Midostaurin and its major active metabolites CGP62221 and CGP52421 inhibit the activity of protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and WT and/or mutant FLT3 tyrosine kinases. Inhibition of FLT3 receptor signalling cascades induces apoptosis of target leukemia cells expressing target receptors and mast cells, in addition to its antiproliferative activity toward multiple cancer cell lines. Midostaurin also interacts with organic anion transporter (OATP) 1A1 and multidrug resistance protein (MRP)-2 according to preliminary in vitro studies.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35231
Submission : 2020-09-28
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2020-10-26
Pay. Date : 2020-09-21
DMF Number : 34665
Submission : 2020-03-31
Status : Active
Type : II
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36640
Submission : 2021-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34990
Submission : 2022-12-21
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-12-04
Pay. Date : 2020-07-03
DMF Number : 34976
Submission : 2020-10-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36606
Submission : 2021-12-25
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-06-28
Pay. Date : 2021-05-05
DMF Number : 35562
Submission : 2021-05-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34522
Submission : 2020-01-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35281
Submission : 2020-11-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-02-02
Pay. Date : 2020-10-09
DMF Number : 35289
Submission : 2020-11-26
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Midostaurin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Midostaurin, including repackagers and relabelers. The FDA regulates Midostaurin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Midostaurin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Midostaurin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Midostaurin supplier is an individual or a company that provides Midostaurin active pharmaceutical ingredient (API) or Midostaurin finished formulations upon request. The Midostaurin suppliers may include Midostaurin API manufacturers, exporters, distributors and traders.
click here to find a list of Midostaurin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Midostaurin DMF (Drug Master File) is a document detailing the whole manufacturing process of Midostaurin active pharmaceutical ingredient (API) in detail. Different forms of Midostaurin DMFs exist exist since differing nations have different regulations, such as Midostaurin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Midostaurin DMF submitted to regulatory agencies in the US is known as a USDMF. Midostaurin USDMF includes data on Midostaurin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Midostaurin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Midostaurin suppliers with USDMF on PharmaCompass.
A Midostaurin written confirmation (Midostaurin WC) is an official document issued by a regulatory agency to a Midostaurin manufacturer, verifying that the manufacturing facility of a Midostaurin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Midostaurin APIs or Midostaurin finished pharmaceutical products to another nation, regulatory agencies frequently require a Midostaurin WC (written confirmation) as part of the regulatory process.
click here to find a list of Midostaurin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Midostaurin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Midostaurin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Midostaurin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Midostaurin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Midostaurin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Midostaurin suppliers with NDC on PharmaCompass.
Midostaurin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Midostaurin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Midostaurin GMP manufacturer or Midostaurin GMP API supplier for your needs.
A Midostaurin CoA (Certificate of Analysis) is a formal document that attests to Midostaurin's compliance with Midostaurin specifications and serves as a tool for batch-level quality control.
Midostaurin CoA mostly includes findings from lab analyses of a specific batch. For each Midostaurin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Midostaurin may be tested according to a variety of international standards, such as European Pharmacopoeia (Midostaurin EP), Midostaurin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Midostaurin USP).
LOOKING FOR A SUPPLIER?